PT Hanamari Mitra Medika
Frequently Asked Question
You May Ask
Thyroid cancer is responsible for 586,000 cases worldwide, ranking in 9th place for incidence in 2020. The global incidence rate in women of 10.1 per 100,000 is 3-fold higher than that in men. Mortality rates from the disease are much lower, with rates of 0.5 per 100,000 in women and 0.3 per 100,000 in men and an estimated 44,000 deaths in both sexes combined [1].
According to 2020 European Thyroid Association Clinical Practice Guideline and European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline, due to the frequent indolent nature, cost, and risk of surgery, image-guided thermal ablation (TA) procedures like microwave ablation has been proposed as non-surgical treatment options for around 3 decades [2][3].
As an alternative option, Image guided Microwave Ablation technology has been widely recommended and used as clinical treatment for thyroid diseases. It is mainly indicated for the treatment of thyroid nodules and thyroid cancers like papillary thyroid microcarcinomas (PTMCs).
Approximately, 2.2 million new cases of lung cancer and 1.8 million lung cancer related deaths were reported in 2020 worldwide. Although the incidence of lung cancer ranks the second in the world, the mortality rate is the highest [1].
By 2022, China and the USA are expected to have approximately 870,982 and 238,032 new lung cancer cases, and 766,898 and 144,913 lung cancer deaths, respectively [2].
For early-stage NSCLC, surgical resection with curative intent comprises the primary therapy, however, approximately 60% of lung cancers cannot be resected surgically due to various reasons. Therefore, microwave ablation, a precise minimally invasive technique, has been applied on treating early-stage lung cancer [3].
As an alternative option, Image guided Microwave Ablation technology has been widely recommended and used as clinical treatment for lung diseases. According to the Lung Clinical Practise Guidelines [3] and Expert Consensus [4], It’s mainly indicated for the treatment of pulmonary subsolid nodules as well as primary and metastatic lung tumors.
Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death world- wide in 2020, with approximately 906,000 new cases and 830,000 deaths. Primary liver cancer includes hepatocellular carcinoma (HCC) (comprising 75%-85% of cases) and intrahepatic cholangiocarcinoma (10%-15%), as wel as other rare types [1].
Traditionally, surgical resection is the reference standard for treatment of patients with hepatic malignancy, however, only a small proportion of patients have the chance to be candidates [2].
As an minimal invasive therapy, image guided Microwave Ablation technology has been widely used as a clinical treatment option for tumors including liver tumor in China [3] and Asia [4]. Microwave Ablation technology has also been recommended by CSCO Guideline (Level of Evidence 1, Recommendation B) [5] and CIRSE Standard Guideline (Level of Evidence 1) [6] as a first line therapy for solitary hepatocellular carcinoma. NCCN Guideline recommend MWA as a suitable option for selected patients (Recommendation 2A) [7].
Kidney cancer is currently the ninth most common cancer in men and the 14th most common in women worldwide. An estimated 431,288 people were diagnosed with kidney cancer in 2020 [1].
Renal cell carcinoma (RCC) comprises more than 90% of kidney cancer. The traditional standard of care for clinically localised RCC is surgical resection. However, not all of patients have the chance to be candidates due to various reasons.
Microwave ablation, as a minimally invasive ablative technologies have emerged as promising treatment options for clinically localised RCC to reduce procedural morbidity while maintaining equivalent oncologic effectiveness with surgery [2]. In China's guidelines, it is mainly indicated for use to treat kidney tumor with a maximum of 3 lesions and a single lesion with a diameter ≤ 4cm (T1a) (Level of Evidence 2-4) [3].
The microwave ablation therapy is also recommended by ACTA Guidelines for RCC (Recommendation B-C) [4] and the EAU Guidelines on RCC [5].
Breast lesions are common and occur frequently in clinical practice. They are prone to various abnormalities and disorders because mammary glands are regulated by endocrine factors [1]. Most breast lesions are benign, only 1%~2% are malignant [2].
Benign breast lesions are the outcomes of proliferation of ductal or lobular tissue that are manifested by the presence of palpable lumps or masses. lts volume will continue to increase, affecting the quality of life for women [3].
The clinical management of breast lesions mainly includes follow-up observation, lesion biopsy, and surgical intervention [1]. So far, surgical intervention, including the breast-conserving surgery(BCS), is an effective way to treat this disease. Yet, some patients are intolerant to surgery because of their poor physical condition and 10% to 40% of patients treated with BCS reported being unsatisfied with cosmetic results for the reason of scar formation and breast asymmetry [3].
In this situation, minimally invasive techniques, such as microwave ablation shows great value to treat benign breast lesions [3].
Uterine fibroids are benign tumors that occur most commonly (70-80%) in women of childbearing age [1] . Fibroids impose a significant psychological burden on affected women. Patients with symptoms often must be treated to alleviate those symptoms [2].
Treatment options for fibroids include hysterectomy, myomectomy, hysteroscopic resection and minimally invasive approaches. Surgical treatment remains the reference standard in the treatment of uterine fibroids; however, it may cause severe trauma and undesirable comorbidity [3].
Actually, not every patient is suitable for the surgical treatment. And improvement in quality of life is a major concern for women evaluating options for fibroids treatment [4]. Thus, increasing attention has been paid to the study of minimally invasive or non-invasive therapies with uterine preservation such as Microwave Ablation [5].
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus nec pretium mi. Curabitur facilisis ornare velit non.
Microwave ablation can generate larger ablation zones in shorter time with less sensibility to heat sink effect.Moreover, MWA radiates all biological issues, such as bone, lung, charred or desiccated tissues. Additionally,multiple antennas can be placed to treat simultaneously for large tumors or multifocal lesion.With CANYON New Generation Microwave Ablation System, the achieved ablation zone can be uniform,homogeneous, and predictable. In addition, a choice of antennas and customized settings provides the user with unique opportunities for clinical diversity during treatment.
- A new portable solid state system to ensure stable microwave output.
- An interactive and sensitive touchscreen with adjustable power, time, and temperature which makes it very user-friendly .
- Continuous and pulsed modes are available for different clinical options.
- Innovative interface which allows the user to monitor and provides instant feedback for safe use .
• Patented radiation control technology and fully cooled antenna that guarantees an ultraspherical shape of the ablation zone
• Enhanced product safety that gives the benefit of strength and stiffness
• New coating which gives the user a perfect and smooth puncture movement, also avoiding tissue adhesion in an efficient way
• Echogenic design that gives the user enhanced visibility
• Available in 14G and 15G in different lengths
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus nec pretium mi. Curabitur facilisis ornare velit non.
- China’s first portable NO inhalation therapy device (NMPA Class III certificate).
- Well-integrated functions: gas instant generation, gas delivery & monitoring.
- Approved for adult and pediatric pulmonary arterial hypertension (PAH).
- Used to treat PPHN, PAH, right heart failure, ARDS syndrome, etc. in NICU, ICU, cardiac surgery, emergency room and respiratory departments.
- CE certification in progress; Certified in Indonesia.
E Katalog 5.0
